CYPHERPUNK TECHNOLOGIES INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $7.45 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $53.90, a 853.98% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $5.65, a 197.37% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.90, a 9.95% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.11, a 17.90% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $7.45, a 49.60% increase from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.98, a 48.82% decline from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $9.73, a 55.06% decline from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $21.65, a 582.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $7.45 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $7.17 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $7.55 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | $53.90 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $4.98 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $5.69 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $6.13 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | $5.65 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $9.73 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $17.29 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $14.42 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $1.90 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | $21.65 10-K · filed 2024-03-18 | $2.17 10-K · filed 2023-03-24 | |||
| 2022-09-30 | $2.17 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $2.10 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $2.11 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $3.17 10-K · filed 2023-03-24 | ||||
| 2021-09-30 | $3.17 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $3.19 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | $2.57 10-Q · filed 2021-05-14 | ||||
| 2020-12-31 | $6.95 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $6.95 10-Q · filed 2020-11-12 | ||||
| 2020-06-30 | $6.96 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $6.87 10-Q · filed 2020-05-14 | ||||
| 2019-12-31 | $15.14 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | $15.14 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $17.04 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $35.10 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $7.89 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $8.22 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $7.25 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $7.24 10-Q/A · filed 2018-08-08 | ||||
| 2017-12-31 | $5.78 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | $5.78 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | $4.86 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | $4.77 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $5.14 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |